[Federal Register Volume 85, Number 136 (Wednesday, July 15, 2020)]
[Notices]
[Pages 42889-42890]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15241]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting; NIH Human Fetal Tissue Research Ethics
Advisory Board--FY2020
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a virtual meeting of the NIH Human
Fetal Tissue Research Ethics Advisory Board--FY2020.
The meeting will be open to the public as indicated below.
Individuals who need special assistance with virtual attendance, such
as sign language interpretation or other reasonable accommodations,
should notify the Contact Person listed below in advance of the
meeting.
The meeting will be closed to the public, as indicated below, in
accordance with the provisions set forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended. The grant and cooperative
agreement applications and R&D contract proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the grant and cooperative agreement applications and
R&D contract proposals, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: NIH Human Fetal Tissue Research Ethics
Advisory Board--FY2020.
Date: July 31, 2020.
Open: 10:00 a.m.-11:05 a.m.
Agenda: Welcome and Charge to the Ethics Advisory Board;
Introduction of Committee Members; Confidentiality and Conflict of
Interest Procedures; Meeting Procedures; and Public Comment Period.
Place: Virtual Meeting/Webcast (link for the meeting will be
available at https://osp.od.nih.gov/biotechnology/nih).
Closed: 11:15 a.m.-4:15 p.m.
Agenda: To make recommendations regarding the ethics of research
involving human fetal tissue (HFT) proposed in NIH grant and
cooperative agreement applications and R&D contract proposals, as
set forth in the NIH Guide Notice NOT-OD-19-128.
Contact Person: Cari Young, ScM, Health Science Policy Analyst,
Office of Science Policy, Office of the Director, National
Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD
20892, 301-496-9838, [email protected].
``This notice is being published less than 15 days prior to the
meeting due to the unforeseen circumstances of COVID-19 which
required the Department's full response and caused a delay in moving
this committee and meeting forward.''
[[Page 42890]]
There will be a 20-minute public comment period during the open
portion of the meeting. Any member of the public interested in
presenting oral comments to the committee, during the public hearing
must notify the Contact Person listed on this notice at least 4 days
in advance of the meeting to reserve a time slot. Interested
individuals and representatives of organizations may submit a letter
of intent, a brief description of the organization represented, and
a short description of the oral presentation. Only one
representative of an organization may be allowed to present and oral
comments will be limited to two minutes. Both printed and electronic
copies are requested for the record. Once all time slots are filled,
only written comments will be accepted. Any interested person may
file written comments with the committee by forwarding their
statement to the Contact Person listed on this notice. The Contact
person should receive any written statements no later than 2 days
before the meeting. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the NIH Office of Science
Policy's web page: https://osp.od.nih.gov/biotechnology/nih-human-
fetal-tissue-research-ethics-advisory-board/ where an agenda, link
to the webcast meeting, and any additional information for the
meeting will be posted when available.
Dated: July 10, 2020.
Natasha M. Copeland,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-15241 Filed 7-14-20; 8:45 am]
BILLING CODE 4140-01-P